News

Genzyme said that under fast track designation, Alemtuzumab for MS is eligible for priority review and the FDA may consider for review portions of the marketing application before

CPLB said that the new facility utilises equipment for fast and efficient production of up to potentially 60 million doses of novel vaccines every year. The facility plans

As per the agreement terms, Icon and Parexel are expected to provide support for Bristol-Myers Squibb’s clinical studies to support its full development pipeline over the next three

As part of the cooperation, Analytik Jena’s subsidiary AJ Innuscreen is expected to provide the partner with a platform for automated isolation of nucleic acids with the associated

The trial, which is to be conducted in the UK, will evaluate the company’s lead drug candidate, MCT-125 for treatment of primary multiple sclerosis-related fatigue (PMSF). MultiCell said

Operating income for the current quarter was $240,000, compared to $704,000 for the same period last year. Net income was $199,000, or $0.01 per share, compared to $657,000,

According Endosense, the Efficas studies are intended to demonstrate that the use of contact force control during cardiac ablation utilizing its TactiCath force-sensing catheter results in superior outcomes

Cook Medical said that PMA submission is a critical step in the product development process, giving the FDA the appropriate information to evaluate the safety and efficacy of

With a motto to serve upstream applications from process development laboratory to the full-scale cGMP production suite, their joint attempt is expected to build on the capabilities of